AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 252 min read$JNJ

J&J's TREMFYA improved spinal pain and stiffness in a 411-person study

Johnson & Johnson (JNJ) reported that TREMFYA met primary and major secondary endpoints in a 411-person study for axial psoriatic arthritis, showing improvement in spinal pain, stiffness, and MRI-measured inflammation. The Phase 4 STAR study demonstrated significant reductions in symptoms and inflammation compared to placebo. Detailed results are forthcoming.

Original reporting
stocktitan.net
Published Sep 25, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial results could expand TREMFYA's market and support higher revenue forecasts, influencing JNJ's overall earnings outlook.

02

Market read

First positive Phase 4 data for an IL-23 inhibitor in axial PsA may drive JNJ stock higher and affect competitor valuations.

03

What to watch

Reimbursement negotiations and payer acceptance for the new indication could limit commercial upside despite positive data.

Relevance 8/10Novelty 9/10Timing: released today

Background

TREMFYA is an IL-23 inhibitor already approved for psoriatic arthritis; this study is the first to demonstrate efficacy on axial symptoms and MRI‑measured inflammation.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson announced TREMFYA met primary and major secondary endpoints in the Phase 4 STAR axial psoriatic arthritis study, a first for an IL-23 inhibitor.

Expected impact

Potential short-term upside as investors price in expanded label and market share gains.

Evidence & confidence

First disclosure of statistically significant efficacy in a new indication for a marketed drug, combined with a recent FDA label expansion, is material for valuation.

Market effects

Sector

Strengthens the biotech/autoimmune therapeutic sector and may pressure competitors in the IL-23 space.

Regional

U.S. market may see modest gains in healthcare stocks; European markets with JNJ ADRs could see similar moves.

Global

Adds to global confidence in biologic therapies for psoriatic arthritis, potentially influencing pipeline decisions worldwide.

Counterpoint

What could challenge this read

If the upcoming detailed data do not confirm the topline results, the initial hype could reverse, leading to a sell-off.

Key entities

  • company
    Johnson & Johnson

    Pharmaceutical division developer of TREMFYA.

  • drug
    TREMFYA (guselkumab)

    IL-23 inhibitor evaluated in the STAR Phase 4 study.

Read at source← All news

Related articles

SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min
SEP 25
$JNJMed

J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?

Johnson & Johnson (JNJ) reported that its drug RYBREVANT, combined with chemotherapy, achieved a median overall survival of 34.3 months in a Phase 3 trial for advanced non-small cell lung cancer, compared to 27.9 months with chemotherapy alone. While the protocol-specified final overall-survival analysis did not reach statistical significance, a prespecified analysis accounting for crossover showed a 43% reduction in the risk of death.

insidermonkey.com3 min